- Trials with a EudraCT protocol (17)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
17 result(s) found for: Androgen Replacement Therapy.
Displaying page 1 of 1.
EudraCT Number: 2011-001638-41 | Sponsor Protocol Number: CLAR-09007 | Start Date*: 2011-10-12 |
Sponsor Name:CLARUS THERAPEUTICS, INC. | ||
Full Title: PHASE III, ACTIVE-CONTROLLED, SAFETY AND EFFICACY TRIAL OF ORAL TESTOSTERONE UNDECANOATE (TU) IN HYPOGONADAL MEN. | ||
Medical condition: Hypogonadal men | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: DE (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-006925-26 | Sponsor Protocol Number: no sponsor | Start Date*: 2007-04-05 |
Sponsor Name:Rijnstate hospital | ||
Full Title: Optimalising the Androgen-Oestrogen Balance in Testosterone Substituted Hypogonadal Men by Aromatase Inhibition. | ||
Medical condition: Men with hypogonadotropic hypogonadism treated with testosterone substitution | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-004266-15 | Sponsor Protocol Number: ARYHM-1 | Start Date*: 2012-01-18 | |||||||||||
Sponsor Name:RMC, Skåne University Hospital | |||||||||||||
Full Title: Androgen replacement in young hypogonadal men: a 2 year randomized, double-blind placebo controlled study | |||||||||||||
Medical condition: Target population: Male hypogonadism (testosterone deficiency) As end points Bone mineralisation Body composition Markers of insulin sensitivity and cardiovascular disease Lipid profile H... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: SE (Ongoing) NO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000458-40 | Sponsor Protocol Number: Infacort004 | Start Date*: 2015-10-20 |
Sponsor Name:Diurnal Limited | ||
Full Title: Open-label, long-term follow-up of safety and biochemical disease control of Infacort® in neonates, infants and children with congenital adrenal hyperplasia and adrenal insufficiency previously enr... | ||
Medical condition: Adrenal Insufficiency (AI) in children is most commonly due to Congenital Adrenal Hyperplasia (CAH) and results in cortisol deficiency with or without aldosterone deficiency and androgen excess. ... | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-000711-40 | Sponsor Protocol Number: DIUR-005 | Start Date*: 2015-11-19 | |||||||||||
Sponsor Name:Diurnal Ltd | |||||||||||||
Full Title: A Phase III study of efficacy, safety and tolerability of Chronocort® compared with standard glucocorticoid replacement therapy in the treatment of congenital adrenal hyperplasia. | |||||||||||||
Medical condition: Congenital adrenal hyperplasia (CAH); is generally due to 21-hydroxylase deficiency, is a disease of the adrenal cortex characterised by cortisol deficiency with or without aldosterone deficiency, ... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) SE (Completed) NL (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005822-23 | Sponsor Protocol Number: REK231814 | Start Date*: 2012-10-16 | |||||||||||
Sponsor Name:Haukeland University Hospital | |||||||||||||
Full Title: CONTINUOUS SUBCUTANEOUS HYDROCORTISONE INFUSION IN CONGENITAL ADRENAL HYPERPLASIA | |||||||||||||
Medical condition: Congenital adrenal hyperplasia (CAH) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Ongoing) SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-006114-14 | Sponsor Protocol Number: 62326B1658 | Start Date*: 2012-04-17 |
Sponsor Name:Research and Development department | ||
Full Title: “Effects of testosterone on glycaemic control and other Cardiovascular Risk factors in Hypogonadal Men with uncontrolled Type 2 Diabetes: A randomized double – blinded placebo controlled add on tr... | ||
Medical condition: Hypogonadism Type 2 Diabetes Cardiovascular risk | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2013-001767-23 | Sponsor Protocol Number: T01/09/13 | Start Date*: 2016-02-29 | |||||||||||||||||||||
Sponsor Name:Seahorse Scientific Services Ltd. | |||||||||||||||||||||||
Full Title: A Single-Dose, Single Period, Phase II Pharmacokinetic Study To Examine TDS®-Testosterone For Its Potential To Be Inadvertently Transferred By Skin Contact After Dosing In Healthy Adult Subjects | |||||||||||||||||||||||
Medical condition: Male Hypogondism | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-002607-17 | Sponsor Protocol Number: TSX/01/C | Start Date*: 2005-11-18 |
Sponsor Name:Prostrakan Pharmaceuticals Ltd | ||
Full Title: Effect of Transdermal Testosterone Replacement in Hypogonadal Men with either Metabolic Syndrome or Type 2 Diabetes Mellitus | ||
Medical condition: Male hypogonadism is generally characterised by abnormally low serum testosterone levels. Symptoms include changes in mood, decreased bone mineral density, increased body fat, decreased muscle mass... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: GB (Completed) DE (Completed) BE (Completed) ES (Completed) SE (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-002265-30 | Sponsor Protocol Number: Infacort003 | Start Date*: 2015-02-19 |
Sponsor Name:Diurnal Limited | ||
Full Title: A Phase 3 open-label study of Infacort® in neonates, infants and children less than 6 years of age with adrenal insufficiency. | ||
Medical condition: Adrenal Insufficiency (AI) in children is most commonly due to Congenital Adrenal Hyperplasia (CAH) and results in cortisol deficiency with or without aldosterone deficiency and androgen excess. Cu... | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-003142-32 | Sponsor Protocol Number: TBR-760-NFPA-201 | Start Date*: 2020-07-16 | |||||||||||
Sponsor Name:Tiburio Therapeutics, Inc. | |||||||||||||
Full Title: A One Year, Randomized, Double-Blind, Placebo-Controlled Study of TBR-760 in Adult Patients with Non-Functioning Pituitary Adenomas | |||||||||||||
Medical condition: Non-Functioning Pituitary Adenomas | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) HU (Prematurely Ended) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002249-13 | Sponsor Protocol Number: 3125001 | Start Date*: 2019-02-04 | ||||||||||||||||
Sponsor Name:Orion Corporation Orion Pharma | ||||||||||||||||||
Full Title: SAFETY AND PHARMACOKINETICS OF ODM-209 IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER OR ESTROGEN RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED BRE... | ||||||||||||||||||
Medical condition: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER OR ESTROGEN RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED BREAST CANCER | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FI (Completed) DK (Completed) ES (Prematurely Ended) IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004982-25 | Sponsor Protocol Number: BET115521 | Start Date*: 2015-08-18 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Ltd | |||||||||||||
Full Title: A phase I/II open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in subjects with NUT midline carcinoma (NMC) and othe... | |||||||||||||
Medical condition: NUT Midline Carcinoma and other solid tumors | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) NL (Completed) ES (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001148-37 | Sponsor Protocol Number: 200182 | Start Date*: 2018-05-25 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A randomized, double-blind (sponsor unblind), placebo-controlled, multi-centered phase IIa study to evaluate the safety and efficacy of 13 weeks of once daily oral dosing of the selective androgen ... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020802-13 | Sponsor Protocol Number: OGX-011-10 | Start Date*: 2010-12-17 | ||||||||||||||||
Sponsor Name:OncoGenex Technologies, Inc. | ||||||||||||||||||
Full Title: A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Clinical Benefit of Adding Custirsen to Docetaxel Retreatment/Prednisone as an Option for Secondline Therapy in Men with... | ||||||||||||||||||
Medical condition: metastatic castrate resistant prostate cancer. cáncer de próstata metastásico hormonoresistente | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||
Trial protocol: ES (Ongoing) GB (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001714-14 | Sponsor Protocol Number: B7981015 | Start Date*: 2019-07-22 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A PHASE 2B/3 RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, DOSE RANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF-06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA (AA) SUBJECTS WITH 50% OR... | |||||||||||||
Medical condition: Alopecia areata | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) HU (Completed) CZ (Completed) PL (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000345-39 | Sponsor Protocol Number: B9991032 | Start Date*: 2019-02-19 | ||||||||||||||||
Sponsor Name:Pfizer Inc. | ||||||||||||||||||
Full Title: A Phase 2 Study to Evaluate Safety and Anti-tumor Activity of Avelumab in Combination with Talazoparib In Patients with BRCA or ATM Mutant Tumors | ||||||||||||||||||
Medical condition: locally advanced (primary or recurrent) or metastatic solid tumors with a pathogenic or likely pathogenic germline or loss-of-function somatic BRCA1, or BRCA2, or ATM gene defect | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) FR (Completed) BE (Completed) DK (Completed) ES (Ongoing) IT (Ongoing) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.